摘要
目的:研究香菇多糖(lentinan,LNT)对急性髓细胞性白血病(acute myeloid leukemia,AML)患者树突状细胞(den-dritic cell,DC)成熟及功能的影响,探索白血病免疫治疗的新途径。方法:分离AML完全缓解期患者(AML-complete remis-sion,AML-CR)的骨髓单个核细胞(bone marrowmononuclear cell,BMC),用GM-CSF和IL-4诱导7d培养DC,然后分组:LPS阳性对照组、LNT实验组和对照组。培养48h后以瑞氏-吉姆萨(Wright-Giemsa)染色观察各组DC形态,流式细胞术检测各组DC表面分子CD80、CD83、CD86、CD1a和HLA-DR的表达,ELISA法检测各组DC上清液中IL-12的水平。免疫磁珠法分离AML-CR患者经LNT治疗后的外周血DC,ELISA法检测治疗后DC上清液中IL-12的水平。结果:体外实验中,LNT处理后DC呈典型树突状形态;其表面分子CD80、CD83、CD86、CD1a及HLA-DR的表达上调(P<0.05);DC分泌IL-12较阴性对照组显著增高(P<0.05),且呈LNT浓度依赖性。患者体内试验结果显示,LNT治疗后AML患者的DC上清液中IL-12分泌水平较治疗前显著提高(P<0.05)。结论:LNT在体内外均能促进AML患者的DC成熟和增强DC功能。
Objective:To study the effects of lentinan(LNT)on maturation and function of dendritic cells(DCs)of acute myeloid leukemia(AML)patients,so as to explore new ways for leukemia immunotherapy.Methods:Bone marrow mononuclear cells(BMCs)were isolated from AML complete remission(AML-CR)patients,and were induced to differentiate into DCs by GM-CSF and IL-4 for 7 d.DCs were then divided into 3 groups:LPS positive control group,LNT group,and control group.After 48 h,the morphology of DCs was observed by Wright-Giemsa staining in different groups;CD80,CD83,CD86,CD1α,and HLA-DR expressions on DCs were examined by flow cytometry assay;and IL-12 production was determined by ELISA.DCs of AML patients were isolated from human peripheral blood mononuclear cells(PBMC)by magnetic cell sorting(MACS)after LNT therapy,and the concentration of IL-12 in DC supernatants was determined by ELISA.Results:In vitro,LNT-treated DCs showed a typical DC morphology;it concentration-dependently increased the expressions of CD80,CD83,CD86,CD1a and HLA-DR(P〈0.05)and level of IL-12 compared with the control group(P〈0.05).In vivo,IL-12 in the supernatant of DCs of AML patients after LNT therapy was significantly higher than that of untreated patients(P〈0.05).Conclusion:LNT can promote maturation and function of DCs from AML patients in vivo and in vitro,exrting its anti-tumor effect.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
北大核心
2010年第4期434-438,共5页
Chinese Journal of Cancer Biotherapy
基金
甘肃省科技支撑计划项目(No.0804NKCA115)~~